NZ596946A - Solid compositions comprising 5-aminolevulinic acid - Google Patents
Solid compositions comprising 5-aminolevulinic acidInfo
- Publication number
- NZ596946A NZ596946A NZ596946A NZ59694610A NZ596946A NZ 596946 A NZ596946 A NZ 596946A NZ 596946 A NZ596946 A NZ 596946A NZ 59694610 A NZ59694610 A NZ 59694610A NZ 596946 A NZ596946 A NZ 596946A
- Authority
- NZ
- New Zealand
- Prior art keywords
- solid
- hydrogenated
- triglycerides
- active ingredient
- aminolevulinic acid
- Prior art date
Links
- 229960002749 aminolevulinic acid Drugs 0.000 title abstract 4
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008247 solid mixture Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 abstract 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 abstract 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract 2
- -1 5-ALA ester Chemical class 0.000 abstract 1
- 229920003134 Eudragit® polymer Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 235000019482 Palm oil Nutrition 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940110456 cocoa butter Drugs 0.000 abstract 1
- 235000019868 cocoa butter Nutrition 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229940116364 hard fat Drugs 0.000 abstract 1
- 229940049290 hydrogenated coco-glycerides Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 abstract 1
- 239000002540 palm oil Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003760 tallow Substances 0.000 abstract 1
- 229940113164 trimyristin Drugs 0.000 abstract 1
- 229960001947 tripalmitin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09251538 | 2009-06-11 | ||
| PCT/EP2010/003531 WO2010142456A1 (en) | 2009-06-11 | 2010-06-11 | Solid compositions comprising 5-aminolevulinic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596946A true NZ596946A (en) | 2014-07-25 |
Family
ID=42628133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596946A NZ596946A (en) | 2009-06-11 | 2010-06-11 | Solid compositions comprising 5-aminolevulinic acid |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120134921A1 (enExample) |
| EP (1) | EP2440188A1 (enExample) |
| JP (1) | JP2012529451A (enExample) |
| KR (1) | KR20140014401A (enExample) |
| CN (1) | CN102802612A (enExample) |
| AU (1) | AU2010257752B2 (enExample) |
| BR (1) | BRPI1011650A2 (enExample) |
| CA (1) | CA2763837A1 (enExample) |
| CL (1) | CL2011003115A1 (enExample) |
| CO (1) | CO6480960A2 (enExample) |
| CR (1) | CR20110649A (enExample) |
| MX (1) | MX2011013069A (enExample) |
| NZ (1) | NZ596946A (enExample) |
| PE (1) | PE20120858A1 (enExample) |
| RU (1) | RU2527328C2 (enExample) |
| SG (1) | SG176687A1 (enExample) |
| WO (1) | WO2010142456A1 (enExample) |
| ZA (1) | ZA201108850B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013521251A (ja) * | 2010-03-01 | 2013-06-10 | フォトキュア エイエスエイ | 美容組成物 |
| DE102012105512A1 (de) * | 2012-06-25 | 2014-04-24 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur verlängerten Freisetzung von Wirkstoffen |
| US20140067024A1 (en) | 2012-08-30 | 2014-03-06 | Photocure Asa | Dual panel photodynamic therapy lamp |
| GB201221123D0 (en) | 2012-11-23 | 2013-01-09 | Photocure As | Device for photodynamic treatment |
| KR20150141958A (ko) * | 2013-03-12 | 2015-12-21 | 어플라이드 바이오리서치, 인크. | 개선된 약물 전달을 위한 킬레이트화 좌제 |
| JP6588193B2 (ja) * | 2014-07-31 | 2019-10-09 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ | カプセル製剤 |
| US20170216146A1 (en) * | 2014-07-31 | 2017-08-03 | Capsugel Belgium Nv | Capsule formulation |
| US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
| US9956426B2 (en) | 2015-02-26 | 2018-05-01 | Amol Punjabi | Upconverting nanoparticles |
| AU2016372575B2 (en) | 2015-12-17 | 2022-12-08 | Photocure Asa | Method of photodynamic therapy (PDT) for bladder cancer |
| GB201522398D0 (en) | 2015-12-18 | 2016-02-03 | Photocure As | Device for photodynamic therapy |
| CN105481946B (zh) * | 2015-12-18 | 2019-05-21 | 浙江工商大学 | 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途 |
| US10744212B2 (en) | 2016-03-14 | 2020-08-18 | General Electric Company | Topical application of nerve labeling dyes for image-guided surgery |
| GB2546128A (en) * | 2016-09-28 | 2017-07-12 | Photocure Asa | Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same |
| JP7136807B2 (ja) | 2017-04-17 | 2022-09-13 | ザ・ユニバーシティ・オブ・シカゴ | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 |
| CN107434753A (zh) * | 2017-07-26 | 2017-12-05 | 南京大学 | 5‑氨基乙酰丙酸及其衍生物的泡腾片及其制备方法 |
| PH12020550124B1 (en) | 2017-12-01 | 2024-05-24 | Nat Ct Child Health & Dev | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3181062B2 (ja) * | 1991-01-31 | 2001-07-03 | 帝國製薬株式会社 | 下部消化管崩壊経口製剤 |
| US6492420B2 (en) * | 1995-03-10 | 2002-12-10 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| CZ291132B6 (cs) * | 1995-03-10 | 2002-12-11 | Photocure Asa | Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem |
| EP2127642A3 (en) * | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
| EP1184038B1 (en) * | 1999-06-09 | 2005-12-28 | Mochida Pharmaceutical Co., Ltd. | System for release in lower digestive tract |
| DE10003620A1 (de) * | 2000-01-28 | 2001-08-02 | Asat Ag Applied Science & Tech | 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln |
| GB0018527D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US7264629B2 (en) * | 2001-11-09 | 2007-09-04 | Qlt, Inc. | Photodynamic therapy for the treatment of hair loss |
| TW577606U (en) * | 2001-11-20 | 2004-02-21 | Carry Computer Eng Co Ltd | Improved structure of all-in-one silicon disk |
| DE102005019628A1 (de) * | 2005-04-26 | 2006-11-09 | Technische Universität Braunschweig | Formulierung zur dermalen Anwendung |
| GB0609809D0 (en) * | 2006-05-17 | 2006-06-28 | Photocure Asa | Product |
| GB0724279D0 (en) * | 2007-12-12 | 2008-01-23 | Photocure Asa | Use |
-
2010
- 2010-06-11 CN CN2010800256075A patent/CN102802612A/zh active Pending
- 2010-06-11 NZ NZ596946A patent/NZ596946A/en not_active IP Right Cessation
- 2010-06-11 WO PCT/EP2010/003531 patent/WO2010142456A1/en not_active Ceased
- 2010-06-11 PE PE2011002072A patent/PE20120858A1/es not_active Application Discontinuation
- 2010-06-11 CA CA2763837A patent/CA2763837A1/en not_active Abandoned
- 2010-06-11 SG SG2011090040A patent/SG176687A1/en unknown
- 2010-06-11 AU AU2010257752A patent/AU2010257752B2/en not_active Expired - Fee Related
- 2010-06-11 US US13/377,692 patent/US20120134921A1/en not_active Abandoned
- 2010-06-11 RU RU2011150920/15A patent/RU2527328C2/ru not_active IP Right Cessation
- 2010-06-11 KR KR1020117030694A patent/KR20140014401A/ko not_active Withdrawn
- 2010-06-11 MX MX2011013069A patent/MX2011013069A/es not_active Application Discontinuation
- 2010-06-11 BR BRPI1011650A patent/BRPI1011650A2/pt not_active IP Right Cessation
- 2010-06-11 JP JP2012514392A patent/JP2012529451A/ja not_active Ceased
- 2010-06-11 EP EP10725043A patent/EP2440188A1/en not_active Withdrawn
-
2011
- 2011-12-01 ZA ZA2011/08850A patent/ZA201108850B/en unknown
- 2011-12-05 CR CR20110649A patent/CR20110649A/es unknown
- 2011-12-07 CL CL2011003115A patent/CL2011003115A1/es unknown
- 2011-12-27 CO CO11179486A patent/CO6480960A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120134921A1 (en) | 2012-05-31 |
| AU2010257752B2 (en) | 2015-04-09 |
| ZA201108850B (en) | 2013-02-27 |
| RU2011150920A (ru) | 2013-07-20 |
| EP2440188A1 (en) | 2012-04-18 |
| CN102802612A (zh) | 2012-11-28 |
| CR20110649A (es) | 2012-03-22 |
| RU2527328C2 (ru) | 2014-08-27 |
| PE20120858A1 (es) | 2012-08-01 |
| JP2012529451A (ja) | 2012-11-22 |
| AU2010257752A1 (en) | 2012-01-12 |
| CO6480960A2 (es) | 2012-07-16 |
| WO2010142456A1 (en) | 2010-12-16 |
| SG176687A1 (en) | 2012-01-30 |
| BRPI1011650A2 (pt) | 2016-03-22 |
| CA2763837A1 (en) | 2010-12-16 |
| CL2011003115A1 (es) | 2012-06-22 |
| MX2011013069A (es) | 2012-02-01 |
| KR20140014401A (ko) | 2014-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596946A (en) | Solid compositions comprising 5-aminolevulinic acid | |
| JP2012529451A5 (enExample) | ||
| WO2011060945A3 (en) | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases | |
| HRP20200065T1 (hr) | Upotreba etilnog estera ikozapentaenske kiseline u liječenju hipertrigliceridemije | |
| WO2009091538A8 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
| WO2008027991A3 (en) | USE OF DPA(n-6) OILS IN INFANT FORMULA | |
| HRP20190732T1 (hr) | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti | |
| JP2008540394A5 (enExample) | ||
| SI2443246T1 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| WO2011060944A3 (en) | Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters | |
| EP2213335A3 (en) | Personal care compositions having reduced eye irritation | |
| CA2576196A1 (en) | Novel statin pharmaceutical compositions and related methods of treatment | |
| EP1392276A1 (en) | Potentiation of therapeutic effects of polyunsaturated fatty acids | |
| Wang et al. | The structure of triglycerides impacts the digestibility and bioaccessibility of nutritional lipids during in vitro simulated digestion | |
| NZ716730A (en) | Methods, compositions, and devices for supplying dietary fatty acid needs | |
| WO2009150023A3 (de) | Verfähren zur herstellung von sphingolipiden durch enzymatische n-acylierung von lysosphingolipiden unter verwendung einer lipase und eines fettsäureglycerinesters | |
| MX2009004339A (es) | Alcoholes de acido graso. | |
| HRP20110086T1 (hr) | Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti | |
| EP2213336A3 (en) | Personal care sunscreen compositions having reduced eye irritation | |
| RU2020101477A (ru) | Фармацевтические композиции, содержащие дглк, и их применение | |
| MX2009012782A (es) | Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados. | |
| RU2013112807A (ru) | Композиция для доставки активных агентов в желудок | |
| JP2010508261A (ja) | 新規脂質化合物 | |
| JP2018515463A5 (enExample) | ||
| WO2006111633A3 (fr) | Utilisation de la lecithine comme medicament dans le traitement du psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JUN 2017 BY PHILLIPS ORMONDE FITZPATRICK Effective date: 20150109 |
|
| LAPS | Patent lapsed |